SKU: 1010

5-HTP

5-HTP

Availability: In stock

Price:$45.00

Mood Stabilizer* - Sleep Aid* - Appetite Suppressant* 


Mood disorders, including depression, are associated with serotonin imbalances in the brain. 5-HTP crosses the blood-brain barrier and is decarboxylated to serotonin with the help of vitamin B6 and has been shown to be effective in depressive disorders. Supplementing 5-HTP for those suffering with insomnia has been shown to increase R.E.M sleep from 5 to 53%.1  In addition to its impact on mood disorders and insomnia, 5-HTP has a significant impact on many other conditions including fibromyalgia, migraine headaches and obesity.*

Price:$45.00

Customers Who Bought This Product Also Bought

Product Description

5-HTP for a better mood and improved sleep.

Mood disorders, including depression, are associated with serotonin imbalances in the brain. 5-HTP crosses the blood-brain barrier and is decarboxylated to serotonin with the help of vitamin B6 and has been shown to be effective in depressive disorders. Supplementing 5-HTP for those suffering with insomnia has been shown to increase R.E.M sleep from 5 to 53%.1  In addition to its impact on mood disorders and insomnia, 5-HTP has a significant impact on many other conditions including fibromyalgia, migraine headaches and obesity.*

Additional Impact 5-HTP Can Make On Your Health

Fibromyalgia

Low serotonin is common in those with fibromyalgia. Double-blind research trials have reported that supplementing with 100mg of 5-HTP three times per day relieves some symptoms of fibromyalgia.2-3 Insomnia - 200 mg 2 hrs. before bedtime/400 mg at bedtime A single 100-mg nighttime dose of 5-HTP was sufficient to improve the duration and depth of sleep in one placebo-controlled trial.4 In a double-blind trial of people without insomnia, supplementation with 5-HTP (200 mg at 9:15 p.m. and 400 mg at 11:15 p.m.) increased rapid-eye-movement (REM) sleep, presumably indicating improved sleep quality.5

Migraine Headache 

Forty people with migraine headaches received either 200mg of 5-HTP per day or methysergide (a migraine medication) for forty days. Both compounds reduced the frequency of migraines by 50%.6 Migraine attacks were reduced in frequency, severity, and duration in 90% of those taking 400 mg per day of 5-HTP in a double-blind placebo-controlled trial.7

Obesity

In a 12-week double-blind trial, overweight females took 600 to 900 mg of 5-HTP and lost significantly more weight than those women who received the placebo.8 In another double-blind trial obese people with type 2 diabetes took 750 mg of 5-HTP for two weeks with no dietary restrictions (some reduced their carbohydrate and fat intake voluntarily). The group taking the 5-HTP lost 23 times more weight compared to the placebo group (4.6 pounds vs 0.2 pounds respectively).9

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.



Citations

  1. Wyatt, R. J., et al. "Effects of 5-hydroxytryptophan on the sleep of normal human subjects." Electroencephalography and clinical neurophysiology 30.6 (1971): 505-509.
  2. Puttini PS, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res 1992;20:182-9.
  3. Moldofsky H, Warsh JJ. Plasma tryptophan and musculoskeletal pain in non-articular rheumatism (“fibrositis syndrome”). Pain 1978;5:65-71. 
  4. Soulairac A, Lambinet H. Etudes cliniques de líaction du precurseur de la serotonine le L-5-hydroxy-tryptophane, sur les troubles du sommeil. 
  5. Schweiz Bundschau Med (PRAXIS) 1998;77(34a):19-23 [in French]. 
  6. Wyatt RJ, Zarcone V, Engelman K, et al. Effects of 5-hydroxytryptophan on the sleep of normal human subjects. Electroencephalogr Clin Neurophysiol1971;30:505-9. 
  7. Titus F, Davalos A, Alom J, Codina A. 5-hydroxytryptophan versus methysergide in the prophylaxis of migraine. Eur Neurol 1986;25:327-9. 
  8. De Benedittis G, Massei R. 5-HT precursors in migraine prophylaxis: A double-blind cross-over study with L-5-hydroxytryptophan versus placebo. Clin J Pain1986;3:123-9. 
  9. Cangiano C, Ceci F, Cascino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr1992;56:863–7. 

 


Supplemental Facts

Supplemental Facts

Suggested Use

Suggested Use

Suggested Use:

As a dietary supplement, take one (1) or more capsules per day or as recommended by your health care professional.

Caution:

Do not consume this product if you are pregnant or nursing. As with any dietary supplement, consult your healthcare practitioner before using this product, especially if you take any medication (especially neurological and/or antidepressant medications), anticipate surgery or are otherwise under medical supervision. 

Formulated To Be Free of Allergens Derived From:

Wheat, gluten, soy, dairy, eggs, fish, crustacean shellfish, tree nuts, peanuts, artificial preservatives, sweeteners, colors and flavors.

 

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. 

FAQs

FAQ's

Research

References and Research Abstracts Supporting 5-HTP 

1. Puttini PS, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res 1992;20:182-9.
2. Moldofsky H, Warsh JJ. Plasma tryptophan and musculoskeletal pain in non-articular rheumatism (“fibrositis syndrome”). Pain 1978;5:65-71.
3. Soulairac A, Lambinet H. Etudes cliniques de líaction du precurseur de la serotonine le L-5-hydroxy-tryptophane, sur les troubles du sommeil.
4. Schweiz Bundschau Med (PRAXIS) 1998;77(34a):19-23 [in French].
5. Wyatt RJ, Zarcone V, Engelman K, et al. Effects of 5-hydroxytryptophan on the sleep of normal human subjects. Electroencephalogr Clin Neurophysiol1971;30:505-9.
6. Titus F, Davalos A, Alom J, Codina A. 5-hydroxytryptophan versus methysergide in the prophylaxis of migraine. Eur Neurol 1986;25:327-9.
7. De Benedittis G, Massei R. 5-HT precursors in migraine prophylaxis: A double-blind cross-over study with L-5-hydroxytryptophan versus placebo. Clin J Pain1986;3:123-9.
8. Cangiano C, Ceci F, Cascino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr1992;56:863–7.
9. Cangiano C, Laviano A, Del Ben M, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. Int J Obes Relat Metab Disord 1998;22:648–54.
10. Lindsley JG, Hartmann EL, Mitchell W. Selectivity in response to L-tryptophan among insomniac subjects: a preliminary report. Sleep 1983;6:247-56.
11. Guyton AC, Hall JE. Textbook of Medical Physiology, 9th ed. Philadelphia: W. B. Saunders, 1996.
12. Van Praag HM, Lemus C. Monoamine precursors in the treatment of psychiatric disorders. Nutrition and the Brain, vol. 7, RJ Wurtman, JJ Wurtman, eds. New York: Raven Press, 1986 [review].
13. Van Praag H, de Hann S. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 1980;3:75-83.
14. Angst J, Woggon B, Schoepf J. The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study.Arch Psychiatr Nervenkr 1977;224:175-86.
15. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nimifensine. Acta Psychiatr Scand 1988;78:676-83.
16. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS. L-5-HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine. Br J Psychiatry 1985;147:16-22.
17. D'Elia G, Hanson L, Raotma H. L-tryptophan and 5-hydroxytryptophan in the treatment of depression. A review. Acta Psychiatr Scand 1978;57:239-52 [review].
18. Jangid P, Malik P, Singh P, et al. Comparative study of efficacy of L-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode.Asian J Psychiatr 2013;6:29–34.))
19. Fava M, Rosenbaum JF, MacLaughlin R, et al. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. J Psychiatr Res1990;24:177-84.
20. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand1994;154(suppl):15-8.
21. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand1994;154(suppl):15-8.
22. Puttini PS, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res 1992;20:182-9. Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990;18:201-9.
23. Schneider-Helmert D, Spinweber CL. Evaluation of L-tryptophan for treatment of insomnia: A review. Psychopharmacology (Berlin) 1986;89(1):1-7.
24. Lindsley JG, Hartmann EL, Mitchell W. Selectivity in response to L-tryptophan among insomniac subjects: a preliminary report. Sleep 1983;6:247-56.
25. Bruni O, Ferri R, Miano S, Verrillo E. L-5-Hydroxytryptophan treatment of sleep terrors in children. Eur J Pediatr 2004;163:402-7.
26. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960;10:107-11.
27. Sicuteri F. The ingestion of serotonin precursors (L-5-hydroxytryptophan and L-tryptophan) improves migraine headache. Headache 1973;13:19-22.
28. Maissen CP, Ludin HP. Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine. Schweizerische Medizinische Wochenschrift /Journal Suisse de Medecine 1991;121:1585-90 [in German].
29. Mathew NT. 5-hydroxytryptophan in the prophylaxis of migraine. Headache 1978;18:111-3.
30. Bono G, Criscuoli M, Martignoni E, et al. Serotonin precursors in migraine prophylaxis. Advances in Neurology 1982;33:357-63.
31. De Giorgis G, Miletto R, Iannuccelli M, et al. Headache in association with sleep disorders in children: A psychodiagnostic evaluation and controlled clinical study ñ L-5-HTP versus placebo. Drugs Exp Clin Res 1987;13:425-33.
32. Santucci M, Cortelli P, Rossi PG, et al. L-5-Hydroxytryptophan versus placebo in childhood migraine prophylaxis: a double-blind crossover study. Cephalalgia1986;6:155-7.
33. Guyton AC, Hall JE. Textbook of Medical Physiology, 9th ed. Philadelphia: W. B. Saunders, 1996.
34. Schneider-Helmert D, Spinweber CL. Evaluation of L-tryptophan for treatment of insomnia: A review. Psychopharmacology (Berlin) 1986;89(1):1-7.
35. Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990;18:201-9.
36. Ribeiro CAF. L-5-hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. Headache2000;40:451-6.
37. Edmeads J. Placebos and the power of negative thinking. Headache 1984;24:342-3 [editorial].
38. De Benedittis G, Massei R. Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytrytophan vs. placebo. J Neurosurg Sci 1985;29:239-48. 561-568.

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register